Back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors

Polymyalgia rheumatica (PMR) and PMR-like syndromes are among the most frequent rheumatologic immuno-related adverse events (IRAEs) induced by cancer immunotherapy with “checkpoint inhibitors” (ICIs). Our short communication addresses two key methodological issues laid bare by published literature :...

Descripción completa

Detalles Bibliográficos
Autores principales: Manzo, Ciro, Isetta, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944960/
https://www.ncbi.nlm.nih.gov/pubmed/33707798
http://dx.doi.org/10.5114/reum.2021.102600
_version_ 1783662774768893952
author Manzo, Ciro
Isetta, Marco
author_facet Manzo, Ciro
Isetta, Marco
author_sort Manzo, Ciro
collection PubMed
description Polymyalgia rheumatica (PMR) and PMR-like syndromes are among the most frequent rheumatologic immuno-related adverse events (IRAEs) induced by cancer immunotherapy with “checkpoint inhibitors” (ICIs). Our short communication addresses two key methodological issues laid bare by published literature : 1) how to diagnose PMR and PMR-like syndromes following ICI therapy, 2) how PMR/PMR-like syndromes following ICI therapy are described as adverse drug reactions (ADRs).
format Online
Article
Text
id pubmed-7944960
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie
record_format MEDLINE/PubMed
spelling pubmed-79449602021-03-10 Back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors Manzo, Ciro Isetta, Marco Reumatologia Short Communication Polymyalgia rheumatica (PMR) and PMR-like syndromes are among the most frequent rheumatologic immuno-related adverse events (IRAEs) induced by cancer immunotherapy with “checkpoint inhibitors” (ICIs). Our short communication addresses two key methodological issues laid bare by published literature : 1) how to diagnose PMR and PMR-like syndromes following ICI therapy, 2) how PMR/PMR-like syndromes following ICI therapy are described as adverse drug reactions (ADRs). Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2021-02-28 2021 /pmc/articles/PMC7944960/ /pubmed/33707798 http://dx.doi.org/10.5114/reum.2021.102600 Text en Copyright: © 2021 Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Short Communication
Manzo, Ciro
Isetta, Marco
Back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors
title Back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors
title_full Back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors
title_fullStr Back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors
title_full_unstemmed Back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors
title_short Back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors
title_sort back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944960/
https://www.ncbi.nlm.nih.gov/pubmed/33707798
http://dx.doi.org/10.5114/reum.2021.102600
work_keys_str_mv AT manzociro backtothefutureidentificationandclassificationofpolymyalgiarheumaticaandpolymyalgiarheumaticalikesyndromesfollowingcancerimmunotherapywithcheckpointinhibitors
AT isettamarco backtothefutureidentificationandclassificationofpolymyalgiarheumaticaandpolymyalgiarheumaticalikesyndromesfollowingcancerimmunotherapywithcheckpointinhibitors

Ejemplares similares